Abstracts tagged "Biologicals"

Abstract Number: L11 • ACR Convergence 2023
Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study
Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, Yong-Beom Park and Min-Chan Park, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Patients with ankylosing spondylitis (AS) have a higher risk of cardiovascular events than controls. Although biological disease-modifying anti-rheumatic drugs (bDMARDs) are efficacious in treating…
Abstract Number: 0050 • ACR Convergence 2023
Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease
Maarten van der Linden¹, Sangeeta Kumari¹, Daphne Montizaan¹, Stephanie van Dalen¹, Annemarie Kip¹, Martyn FOSTER², Inge Reinieren¹, Elsa Neubert³, Luise Erpenbeck⁴, Tirza Bruurmijn¹, Peter van Zandvoort¹, Paul Vink¹, Eric Meldrum⁵, Helmuth van Es¹ and Renato Chirivi¹, ¹Citryll BV, Oss, Netherlands, ²Experimental Pathology Consultancy, Benfleet, United Kingdom, ³Leiden Academic Centre for Drug Research, Leiden, Netherlands, ⁴University Medical Center Münster, General Dermatology and Venereology, Münster, Germany, ⁵Citryll BV, Basel, Switzerland
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of multiple inflammatory and autoimmune diseases (Chirivi et al., 2021; DOI: 10.1038/s41423-020-0381-3). Targeting the NETosis pathway…
Abstract Number: 0384 • ACR Convergence 2023
Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR
Bas Dijkshoorn¹, Ting Wang², Gerdur Maria Grondal³, Daisy Vedder⁴, Anna Rudin⁵, Dan Nordstrom⁶, Bjorn Gudbjornsson⁷, Kristina Lend⁸, Till Uhlig⁹, Espen Haavardsholm⁹, Merete L Hetland¹⁰, Marte Schrumpf Heiberg¹¹, Mikkel Østergaard¹², Kim Horslev-Petersen¹³, John Lampa¹⁴, Ronald van Vollenhoven¹⁵, Christian Lood² and Michael Nurmohamed¹⁶, ¹Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, ²University of Washington, Seattle, WA, ³Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ⁴Reade, Amsterdam, Netherlands, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Helsinki University Hospital, Helsinki, Finland, ⁷Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁸Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ⁹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ¹¹Diakonhjemmet Hospital, Oslo, Norway, ¹²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹³Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ¹⁴Stockholm County, Hãsselby, Sweden, ¹⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹⁶Amsterdam University Medical Centers, Kortenhoef, Netherlands
Background/Purpose: The formation of neutrophil extracellular traps (NETs) with extrusion of nuclear, granular and cytosolic components from a dying neutrophil, has been described extensively in…
Abstract Number: 0522 • ACR Convergence 2023
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status
Xenofon Baraliakos¹, Désirée van der Heijde², Pedro Machado³, Victoria Navarro-Compán⁴, Lianne Gensler⁵, Patricia Pertel⁶, Erhard Quebe-Fehling⁶, Aimee Readie⁷, Hanno Richards⁶ and Denis Poddubnyy⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, Immunology, East Hanover, NJ, ⁸Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: SURPASS, a phase 3b randomized controlled study in patients with radiographic axial spondyloarthritis (r-axSpA), found low spinal radiographic progression over 2 years with no…
Abstract Number: 0674 • ACR Convergence 2023
Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
Daiki Sakai¹, Kaichi Kaneko¹, Karin Furukawa², Mai Kawazoe², Yasuo Matsuzawa³ and Toshihiro Nanki², ¹Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ³Division of Respiratory Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, hyper-eosinophilia, and progressive multiorgan organ involvement. Mepolizumab (MPZ) is a humanized monoclonal…
Abstract Number: 1025 • ACR Convergence 2023
Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients
Sharon Dowell¹, Mercedes Quinones², Tahereh Jamshidi³, Ilona Jileaeva⁴, Oshoze Kadiri⁴ and Gail Kerr⁵, ¹NEA Baptist Memorial Hospital, Jonesboro, AR, ²Washington DC VA Medical Center, Bethesda, MD, ³Howard University Hospital, Bethesda, MD, ⁴Howard University, Washington, DC, ⁵Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: A successful treat to target (T2T) strategy in ethnic minority (EM) patients with rheumatoid arthritis (RA) could improve patient outcomes and help reduce healthcare…
Abstract Number: 1267 • ACR Convergence 2023
Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao fan Fang¹, Lai-Chu See² and Shu-Hao Chang², ¹Chang-Gung Memorial Hospital – Linkou, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan City, Taiwan
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) have become the primary treatment option for rheumatoid arthritis (RA) from 2010 in Taiwan. Tocilizumab is an interleukin-6 receptor…
Abstract Number: 1417 • ACR Convergence 2023
Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration
Marion Pons¹, Simon Horskjær Rasmussen¹, Sara Nysom Christiansen¹, Brigitte Michelsen², Bente Glintborg¹, Bjorn Gudbjornsson³, Gerdur Maria Grondal⁴, Jiri Vencovsky⁵, Anne Gitte Loft⁶, Ziga Rotar⁷, Katja Perdan Pirkmajer⁸, Michael Nissen⁹, Burkhard Moeller¹⁰, Gary Macfarlane¹¹, Gareth T. Jones¹¹, Florenzo Iannone¹², Roberto F. Caporali¹³, Karin Laas¹⁴, Sigrid Vorobjov¹⁵, Daniela Di Giuseppe¹⁶, Belkis Nihan Coskun¹⁷, Burcu Yagız¹⁷, Sella Provan¹⁸, Karen Fagerli¹⁸, Isabel Castrejon¹⁹, Lucia Otero-Valera²⁰, Marleen van de Sande²¹, Irene van der Horst-Bruinsma²², Dan Nordstrom²³, Laura Kuusalo²⁴, Elsa Vieira-Sousa²⁵, Miguel Bernardes²⁶, Tor Olofsson²⁷, Jana Baranová²⁸, Merete Hetland¹, Mikkel Østergaard²⁹ and Lykke Ørnbjerg¹, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ⁵Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Aarhus University, Horsens, Denmark, ⁷University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸University Medical Centre Ljubljana; University of Ljubljana, Ljubljana, Slovenia, ⁹Geneva University Hospitals, Geneva, Switzerland, ¹⁰Inselspital - University Hospital Bern, Bern, Switzerland, ¹¹Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ¹²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ¹⁴Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ¹⁵National Institute for Health Development, Tallinn, Estonia, ¹⁶Karolinska Institutet, Stockholm, Sweden, ¹⁷Department of Rheumatology, Bursa Uludag University, Bursa, Turkey, ¹⁸Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Hospital Universitario Gregorio Marañón, Madrid, Spain, ²⁰Spanish Society of Rheumatology, Madrid, Spain, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²³Helsinki University Hospital, Helsinki, Finland, ²⁴Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ²⁵Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ²⁶Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ²⁷Lund University and Skåne University Hospital, Lund, Sweden, ²⁸Institute of Biostatistics and Analyses, Brno, Czech Republic, ²⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Patient reported outcomes (PROs) are important in the treatment evaluation of patients with spondyloarthritis, including axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). For secukinumab,…
Abstract Number: 1617 • ACR Convergence 2023
Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022
Eric Roberts¹, Jing Li¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski¹, Gabriela Schmajuk⁴ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, HI, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: The first infliximab biosimilar (infliximab-dybb) entered the U.S. market in 2016, and two additional products have subsequently been introduced (infliximab-axxq (2017) and infliximab-abda (2020)).…
Abstract Number: 2113 • ACR Convergence 2023
Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies
Grace Wright¹, Eduardo Mysler², Kevin Roberts³, Lindsay Sweet⁴ and Ahmed Shelbaya⁵, ¹Grace C Wright MD PC, New York, NY, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³Pfizer Inc., Cambridge, MA, ⁴Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., New York, NY
Background/Purpose: Sociodemographic factors can impact treatment response and safety outcomes in patients (pts) with RA. Here, we explore the impact of sociodemographic index (SDI) on…
Abstract Number: 2231 • ACR Convergence 2023
Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis
Dennis McGonagle¹, Arthur Kavanaugh², Iain McInnes³, Lars Erik⁴, Joseph Merola⁵, Bruce Strober⁶, Rebecca Bolce⁷, Jeffrey Lisse⁷, Jennifer Pustizzi⁷, Christophe Sapin⁷ and Christopher T Ritchlin⁸, ¹Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁶Yale University, New Haven, CT, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Nail psoriasis (PsO) is a strong predictor for the development of psoriatic arthritis (PsA) and has been reported in 63–83% of patients with PsA1.…
Abstract Number: 2347 • ACR Convergence 2023
Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials
Saira Sheikh¹, Amit Saxena², Angela Carroll³, Christine Henning³, Julia HN Harris⁴, Bernard Rubin⁵, David D'Cruz⁶ and Alvin F Wells⁷, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²New York University Grossman School of Medicine, Rheumatology, New York, NY, ³GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁶Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom, ⁷Advocate Health Department of Rheumatology, Franklin, WI
Background/Purpose: Belimumab (BEL) is approved for the treatment of active SLE, and lupus nephritis, with standard therapy.1 The prevalence and severity of SLE tend to…
Abstract Number: 2551 • ACR Convergence 2023
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Ioannis Parodis¹, Julius Lindblom¹, Roger A. Levy², Margherita Zen³, Nursen Cetrez¹, Alvaro Gomez⁴, Shereen Oon⁵, Christine Henning⁶, Munther Khamashta⁷, Holly A. Quasny⁸, Deven Chauhan⁹, Anca Askanase¹⁰, Ronald van Vollenhoven¹¹ and Mandana Nikpour¹², ¹Karolinska Institutet, Stockholm, Sweden, ²GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ³University of Padua, Division of Rheumatology, Department of Medicine, Padua, Italy, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ⁶GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁷GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁸GlaxoSmithKline, Research & Development, Durham, NC, ⁹GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…
Abstract Number: 0078 • ACR Convergence 2023
Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal¹, Irene Monjo², Mariela Uyaguari-Morocho¹, Alejandro Villalba³, Laura Nuño¹, Diana Peiteado¹, Elisa Fernández¹, Sara García-Carazo¹ and Alejandro Balsa⁴, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²University Hospital La Paz, Madrid, Spain, ³Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: CD4+CXCR5+PD-1hi follicular helper (Tfh) T cells dwell in the germinal centers (GCs), help B cells, and are implicated in Rheumatoid Arthritis (RA) pathogenesis. Circulating…
Abstract Number: 0391 • ACR Convergence 2023
Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapää-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹⁰, Virginia Pascual Ramos¹¹, Irazú Contreras Yañez¹², Iris Colunga¹³, Dionicio A. Galarza-Delgado¹³, José Ramón Azpiri-López¹³, Silvia Rolefstad¹⁴, Anne Grete Semb¹⁵, Durga P Misra¹⁶, Ellen Margrethe Hauge¹⁷ and GEORGE KITAS¹⁸, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁵Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷Aarhus University Hospital, Aarhus, Denmark, ¹⁸The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Chronic inflammation contributes to enhanced cardiovascular risk in rheumatoid arthritis (RA). Biologic disease modifying antirheumatic drugs (bDMARDs) control inflammation in many conventional synthetic DMARD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].